Multi-center, open-label, Phase 1b study in patients with relapsed/refractory multiple myeloma (RRMM)

Trial Identifier: TCD15484
Sponsor: Sanofi
Start Date: August 2019
Primary Completion Date: March 2024
Study Completion Date: March 2024
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AUSTRALIA, New South Wales Blacktown, New South Wales, AUSTRALIA, 2148
AUSTRALIA, New South Wales Wollongong, New South Wales, AUSTRALIA, 2500
AUSTRALIA, Victoria Fitzroy, Victoria, AUSTRALIA, 3065
AUSTRALIA, Victoria Richmond, Victoria, AUSTRALIA, 3121
BELGIUM Leuven, BELGIUM, 3000
FRANCE Nantes, FRANCE, 44093
FRANCE TOULOUSE Cedex 9, FRANCE, 31059
JAPAN, Okayama Okayama-shi, Okayama, JAPAN, 701-1192
JAPAN, Tokyo Shibuya-ku, Tokyo, JAPAN, 150-8935
SPAIN, Cantabria Santander, Cantabria, SPAIN, 39008
SPAIN, Catalunya [Cataluña] Badalona, Catalunya [Cataluña], SPAIN, 08916
UNITED STATES, Arizona Gilbert, Arizona, UNITED STATES, 85234
UNITED STATES, California Duarte, California, UNITED STATES, 91010
UNITED STATES, Ohio Canton, Ohio, UNITED STATES, 44718